risks of glp-1 drugs Nutritional Side Effects Drugs: Deficiencies, Muscle Loss, and What to Monitor America's Poison Centers - GLP-1
Description
In insulin resistance, cells stop responding properly to insulin
doi: 10.1677/joe.0.1380159 [DOI] [PubMed] [Google Scholar] 57
Additionally, the phase 2 MOMENTUM clinical trial of pemvidutide (a dual GLP-1/GCG agonist) showed that only 21.9% of WL was attributable to reductions in lean mass at 48 weeks (overall WL 10.315.6% across doses) [64]
We can pull more granular data from our patient records than from the national database, Dr
